Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide Regimen

Preferred Label : Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide Regimen;

NCIt synonyms : Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib/Rituximab; TEDDI-R; Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib/Rituximab Regimen; TEDDI-R Regimen; Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib and Rituximab; TEDDI Plus Rituximab; Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide;

NCIt definition : A regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, ibrutinib, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.;

NCI Metathesaurus CUI : CL1663372;

Details

Origin ID

C180769;

UMLS CUI

C5556616;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Dexamethasone Sodium Phosphate [NCIt concept]
- Etoposide [NCIt concept]
- Ibrutinib [NCIt concept]
- Pegylated Liposomal Doxorubicin Hydrochloride [NCIt concept]
- Rituximab [NCIt concept]
- Temozolomide [NCIt concept]
concept_is_in_subset
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients